SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Lauer GM, Walker BD. Hepatitis C virus infection. N. Engl. J. Med. 2001; 345: 4152.
  • 2
    Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36 (5 Suppl. 1): S21S29.
  • 3
    McOmish F, Yap PL, Dow BC et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J. Clin. Microbiol. 1994; 32: 88492.
  • 4
    McCaughan GW. Asian perspectives on viral hepatitis: hepatitis C virus infection. J. Gastroenterol. Hepatol. 2000; 15 (Suppl. ): G903.
  • 5
    Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout Egypt. J. Infect. Dis. 2000; 182: 698707.
  • 6
    Al Faleh FZ, Huraib S, Sbeih F et al. Hepatitis C virus genotypes in patients with chronic liver disease and haemodialysis patients from Saudi Arabia. J. Viral Hepat. 1995; 2: 2936.
  • 7
    Al Faleh FZ, Ramia S, Arif M et al. Profile of hepatitis C virus and the possible modes of transmission of the virus in the Gizan area of Saudi Arabia: a community-based study. Ann. Trop. Med. Parasitol. 1995; 89: 4317.
  • 8
    Osoba AO. Hepatitis C virus genotypes in Saudi Arabia. Saudi Med. J. 2002; 23: 712.
  • 9
    Boriskin YS, Bakir TM, Al Aska AI, Booth JC. Is hepatitis C virus genotype 4 predominant in Saudi Arabia? N. Microbiol. 1999; 22: 17380.
  • 10
    Shobokshi OA, Serebour FE, Skakni L, Al Saffy YH, Ahdal MN. Hepatitis C genotypes and subtypes in Saudi Arabia. J. Med. Virol. 1999; 58: 448.
  • 11
    Koshy A, Madda JP, Marcellin P, Martinot M. Treatment of hepatitis C virus genotype 4-related cirrhosis: ribavirin and interferon combination compared with interferon alone. J. Clin. Gastroenterol. 2002; 35: 825.
  • 12
    Koshy A, Marcellin P, Martinot M, Madda JP. Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis. Liver 2000; 20: 3359.
  • 13
    Ramia S, Koussa S, Taher A et al. Hepatitis-C-virus genotypes and hepatitis-G-virus infection in Lebanese thalassaemics. Ann. Trop. Med. Parasitol. 2002; 96: 197202.
  • 14
    Fretz C, Jeannel D, Stuyver L et al. HCV infection in a rural population of the Central African Republic (CAR): evidence for three additional subtypes of genotype 4. J. Med. Virol. 1995; 47: 4357.
  • 15
    Oni AO, Harrison TJ. Genotypes of hepatitis C virus in Nigeria. J. Med. Virol. 1996; 49: 17886.
  • 16
    Ndjomou J, Kupfer B, Kochan B, Zekeng L, Kaptue L, Matz B. Hepatitis C virus infection and genotypes among human immunodeficiency virus high-risk groups in Cameroon. J. Med. Virol. 2002; 66: 17986.
  • 17
    Hayashi K, Fukuda Y, Nakano I et al. Prevalence and characterization of hepatitis C virus genotype 4 in Japanese hepatitis C carriers. Hepatol. Res. 2003; 25: 40914.
  • 18
    Sanchez-Quijano A, Abad MA, Torronteras R et al. Unexpected high prevalence of hepatitis C virus genotype 4 in Southern Spain. J. Hepatol. 1997; 27: 259.
  • 19
    Cicciarello S, Borgia G, Crowell J et al. Prevalence of hepatitis C virus genotypes in southern Italy. Eur. J. Epidemiol. 1997; 13: 4954.
  • 20
    Matera G, Lamberti A, Quirino A et al. Changes in the prevalence of hepatitis C virus (HCV) genotype 4 in Calabria, Southern Italy. Diagn. Microbiol. Infect. Dis. 2002; 42: 16973.
  • 21
    Remy AJ, Verdier E, Perney P et al. Route of infection, liver histology and response to interferon in patients with chronic hepatitis caused by genotype 4 HCV infection in a Western country (Letter). J. Hepatol. 1998; 29: 169.
  • 22
    Al Faleh FZ, Aljumah A, Rezeig M et al. Treatment of chronic hepatitis C genotype IV with interferon-ribavirin combination in Saudi Arabia: a multicentre study. J. Viral Hepat. 2000; 7: 28791.
  • 23
    Frank C, Mohamed MK, Strickland GT et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 88791.
  • 24
    Rao MR, Naficy AB, Darwish MA et al. Further evidence for association of hepatitis C infection with parenteral schistosomiasis treatment in Egypt. BMC Infect. Dis. 2002; 2: 17.
  • 25
    Abdel-Aziz F, Habib M, Mohamed MK et al. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology 2000; 32: 11115.
  • 26
    Medhat A, Shehata M, Magder LS et al. Hepatitis C in a community in Upper Egypt: risk factors for infection. Am. J. Trop. Med. Hyg. 2002; 66: 6338.
  • 27
    Habib M, Mohamed MK, Abdel-Aziz F et al. Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity. Hepatology 2001; 33: 24853.
  • 28
    Kassem AS, El Nawawy AA, Massoud MN, El Nazar SY, Sobhi EM. Prevalence of hepatitis C virus (HCV) infection and its vertical transmission in Egyptian pregnant women and their newborns. J. Trop. Pediatr. 2000; 46: 2313.
  • 29
    Yeung LT, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology 2001; 34: 2239.
  • 30
    Zylberberg H, Chaix ML, Brechot C. Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-α (Letter). Ann. Intern. Med. 2000; 132: 8456.
  • 31
    Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin. Liver Dis. 1995; 15: 4163.
  • 32
    Lau JY, Davis GL, Prescott LE et al. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Hepatitis Interventional Therapy Group. Ann. Intern. Med. 1996; 124: 86876.
  • 33
    Wali H, Heydtmann M, Harrison R, Hubscher S, Gunson B, Mutimer D. Rapid fibrosis in hepatitis C virus genotype 4 (HCV4) patients after liver transplantation (Abstract). J. Hepatol. 2002; 36: 43A.
  • 34
    Zekry A, Whiting P, Crawford D et al. Liver transplantation for HCV-associated liver cirrhosis: predictors of outcomes in a population with significant genotype 3 and 4 distribution. Liver Transpl. 2003; 9: 33947.
  • 35
    Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 142632.
  • 36
    McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1998; 339: 148592.
  • 37
    Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N. Engl. J. Med. 2000; 343: 166672.
  • 38
    Heathcote EJ, Shiffman ML, Cooksley WG et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 2000; 343: 167380.
  • 39
    Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002; 347: 97582.
  • 40
    Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 95865.
  • 41
    Al Faleh FZ, Sbeih F, Al Karawi M et al. Treatment of chronic hepatitis C genotype 4 with alpha-interferon in Saudi Arabia: a multicenter study. Hepatogastroenterology 1998; 45: 48891.
  • 42
    El Zayadi A, Simmonds P, Dabbous H, Prescott L, Selim O, Ahdy A. Response to interferon-alpha of Egyptian patients infected with hepatitis C virus genotype 4. J. Viral Hepat. 1996; 3: 2614.
  • 43
    Huraib S, Tanimu D, Romeh SA et al. Interferon-alpha in chronic hepatitis C infection in dialysis patients. Am. J. Kidney Dis. 1999; 34: 5560.
  • 44
    El Zayadi A, Selim O, Haddad S et al. Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients. Ital. J. Gastroenterol. Hepatol. 1999; 31: 4725.
  • 45
    Bruno S, Crosignani A, Pinzello GB. Hepatitis C virus genotype 4 and response to combination therapy with interferon-alpha2b plus ribavirin (Letter). Ann. Intern. Med. 2000; 133: 9223.
  • 46
    Sherman M, Marinos G, Sedarati F. Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-α (Letter). Ann. Intern. Med. 2001; 135: 9278.
  • 47
    Shobokshi O, Serebour E, Shakni L et al. Combination therapy of peginterferon alfa-2a (40KD) (Pegasys®) and ribavirin (copegus®) significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia (Abstract). Hepatology 2003; 38: 636A..
  • 48
    Esmat G, Abouzied A, Abdel-Aziz F et al. Treatment with PEG-IFN alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin on subjects with chronic hepatitis C infected with HCV genotype 4 (Abstract). Hepatology 2002; 36: 364A.
  • 49
    Diago M, Hadziyannis S, Bodenheimer H et al. Optimized virological response in genotype 4 chronic hepatitis C patients treated with PEG-IFN alfa-2a (Pegasys) in combination with ribavirin (Abstract). Hepatology 2002; 36: 804A.
  • 50
    Al Faleh FZ, Hadad K, Khuroo M et al. Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Emirates pan-Arab gastroenterology week, 2004.
  • 51
    Hasan F, Asker H, Al Khaldi J et al. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in middle eastern patients. Emirates Pan-Arab Gastroenterology week 2004.